SynthesisFrontiers in clinical diabetes and healthcare2025
Skin autofluorescence is associated with blood glucose levels, especially in children with type 1 diabetes.
Synthesis in Frontiers in clinical diabetes and healthcare, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study examines the correlation between skin autofluorescence (SAF) and blood glucose levels, emphasizing the accumulation of advanced glycation end-products (AGEs). We hypothesize that SAF levels are closely linked to type 1 diabetes complications in children. The aim is to evaluate SAF's relationship with type 1 diabetes progression in children and its potential as a non-invasive tool for disease detection and monitoring complications. The research was registered with PROSPERO (CRD42021284774). Methods: We conducted a meta-analysis by extracting studies from databases including PubMed, MEDLINE, EMBASE, Cochrane, Science Direct, Scopus, and Web of Science. A random effects model was used to assess if SAF measurement could serve as a non-invasive marker for type 1 diabetes and its complications. SAF values were compared between children with type 1 diabetes and controls, calculating the mean difference and 95% confidence intervals. Results: The analysis included three case-control studies and one retrospective cohort study, all using the AGE Reader Conclusion: This research supports SAF measurement as a non-invasive indicator for type 1 diabetes and its complications in children. However, further studies with larger samples and longer follow-up are needed for definitive conclusions and detailed insights into complications. Additionally, the skin's multifaceted roles require further investigation. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42021284774.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.